Sugi Predict

Sugi Predict / Compounds / SCHEMBL8531256

SCHEMBL8531256

SCHEMBL8531256

Cc1cc2ncc(-c3cc(F)c[nH]c3=O)n2nc1NC(C)c1ncc(F)cn1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ JAK2 O60674 12/20 0.35
▸ JAK3 P52333 9/20 0.35
▸ NTRK1 P04629 8/20 0.34
▸ AURKB Q96GD4 3/20 0.33
▸ CDK2 P24941 2/20 0.33
▸ STAT5B P51692 2/20 0.33
▸ IDH1 O75874 2/20 0.33
▸ AURKA O14965 3/20 0.32
▸ RET P07949 2/20 0.32
▸ FGFR1 P11362 2/20 0.32
▸ CSNK2A2 P19784 2/20 0.32
▸ FLT3 P36888 2/20 0.32
▸ PLK4 O00444 1/20 0.32
▸ STK10 O94804 1/20 0.32
▸ PAK4 O96013 1/20 0.32
▸ FER P16591 1/20 0.32
▸ JAK1 P23458 1/20 0.32
▸ TYK2 P29597 1/20 0.32
▸ STAT3 P40763 1/20 0.32
▸ STAT5A P42229 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8531250 1.00 JAK2 (0.35) JAK2JAK3NTRK1AURKBCDK2
SCHEMBL9903803 0.88 JAK3 (0.38) JAK2JAK3NTRK1AURKBCDK2
SCHEMBL9902199 0.88 ATR (0.35) JAK2JAK3NTRK1AURKBCDK2
SCHEMBL9902207 0.88 ATR (0.35) JAK2JAK3NTRK1AURKBCDK2
SCHEMBL9903726 0.83 ALK (0.45) NTRK1CDK2ALK
SCHEMBL9903730 0.83 ALK (0.45) NTRK1CDK2ALK
SCHEMBL8512752 0.77 JAK3 (0.39) JAK2JAK3NTRK1AURKBCDK2
SCHEMBL9903474 0.72 NTRK1 (0.46) JAK2JAK3NTRK1CDK2FGFR1
SCHEMBL9905682 0.71 ALK (0.44) NTRK1CDK2ALK
SCHEMBL9902785 0.71 ALK (0.44) NTRK1CDK2ALK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9133200-B2 Imidazo[1,2-b]pyridazine and imidazo[4,5-b]pyridine derivatives as JAK inhibitors ALMIRALL, S.A. (ES) 2015-09-15 — — US claimed
US-20130309200-A1 IMIDAZO [1,2-B] PYRIDAZINE AND IMIDAZO [4,5-B] PYRIDINE DERIVATIVES AS JAK INHIBITORS ALMIRALL, S.A. (ES) 2013-11-21 — — US claimed
EP-2463289-A1 Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors Almirall, S.A. (ES) 2012-06-13 — — EP claimed
US-9133200-B2 Imidazo[1,2-b]pyridazine and imidazo[4,5-b]pyridine derivatives as JAK inhibitors ALMIRALL, S.A. (ES) 2015-09-15 — — US disclosed
US-20130309200-A1 IMIDAZO [1,2-B] PYRIDAZINE AND IMIDAZO [4,5-B] PYRIDINE DERIVATIVES AS JAK INHIBITORS ALMIRALL, S.A. (ES) 2013-11-21 — — US disclosed
EP-2643321-A1 IMIDAZO [1,2-B]PYRIDAZINE AND IMIDAZO [4,5-B]PYRIDINE DERIVATIVES AS JAK INHIBITORS Almirall S.A. (ES) 2013-10-02 — — EP disclosed
EP-2463289-A1 Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors Almirall, S.A. (ES) 2012-06-13 — — EP disclosed
WO-2012069202-A1 IMIDAZO [1,2-B] PYRIDAZINE AND IMIDAZO [4,5-B] PYRIDINE DERIVATIVES AS JAK INHIBITORS ALMIRALL,S.A. (ES) 2012-05-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130309200-A1 IMIDAZO [1,2-B] PYRIDAZINE AND IMIDAZO [4,5-B] PYRIDINE DERIVATIVES AS JAK INHIBITORS JAK1, JAK2, JAK3 JAK2 2/4885JAK3 3/4885NTRK1 2216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.